STALICLA
STALICLA is delighted to announce the appointment of Stéphane Baudouin as Chief of Science effective from October 10, 2019. Stéphane takes over as Chief of Science from Luigi Boccuto, who will continue as Assistant Research Scientist at Greenwood Genetic Center (SC, USA).
STALICLA will pursue its collaboration with the Greenwood Genetic Center, which is a leading translational research center in genetics and neurodevelopmental disorders, including ASD.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191017005803/en/
Dr. Baudouin is a neurobiologist with extensive research experience in the pathophysiology of Autism Spectrum Disorder. His previous work focused on the identification of molecular pathways and neuronal networks involved in the development of social skills and their breakdown in pathological conditions. Before joining STALICLA, Stéphane was a Senior Lecturer and Team Leader at Cardiff University working on research projects funded by the Wellcome Trust and the Welsh Government. Stéphane has extensive track record of collaboration within the ASD basic and translational research community notably on ASD pharmacology related research. His work has been published in numerous high impact peer-reviewed scientific journals.
Commenting on the appointment, Stéphane said:
“My decision to join STALICLA was motivated by the need to bring tangible advancement to how ASD is treated and real change to the lives of people living with these disorders. STALICLA’s approach to bringing personalized treatments to the neurodevelopmental disorder field is unique and potentially transformational. I’m excited to be part of this team and apply my experience to achieve this goal.”
Stéphane was an active member of STALICLA’s Scientific Advisory Board for over two years prior to taking up the new position. As Chief of Science, he will have overall responsibility to shape STALICLA’s pre-clinical development strategy. He will also be in charge of identifying and managing novel partnerships to support STALICLA’s regulatory needs.
“Stéphane’s extensive experience in the cellular and molecular underpinnings of Autism Spectrum Disorder will be invaluable to our research which focuses on the translation of biological and clinical data to develop precision therapeutics for patients with ASD. He is an incredibly talented addition to our team of experts and I wish him every success in his new role as Chief of Science.”
said Lynn Durham, STALICLA’s CEO & Founder
About STALICLA
STALICLA is a near clinical Company developing a first in class precision medicine platform to accelerate drug development for patients with Neurodevelopmental Disorders (NDD). First focus of development has been Autism Spectrum Disorder (ASD). Today, patients diagnosed with ASD account for 1-1.5% of the world population. The condition remains a high unmet medical need.
In its Geneva and Barcelona units, STALICLA has assembled a world class team of experienced drug developers and computational biologists. The company is recognized as a disruptive player, using its DEPIv3 innovative systems biology AI platform. DEPIv3 integrates domain specific large-scale genetic, molecular, pharmacological and clinical data to define patient subgroups and to identify personalized treatments.
It is the first time that such technologies have been utilized within the field of neurodevelopment with the potential to change the direction of the specialty.
In just over 2 years, the STALICLA platform has already proven successful in expediting and de-risking drug development for a first subgroup of patients with Autism and identifying two additional subgroups.
STALICLA’s first therapeutic package - STP1 - addresses this first distinct subgroup of ASD patients estimated to 1.5 - 2M people in the EU and North America. Clinical entry for STP1 is planned in Q1 2020.
To support its platform and pipeline development, STALICLA has developed a network of top tier research and clinical partners in the US.
This has enabled STALICLA to gather one of the largest Autism patients Electronic Health Records database to date.
STALICLA is currently scaling up DEPIv3 to advance new pipelines for additional groups of patients with NDDs.
For more information : http://www.stalicla.com/news/stalicla-pre-ind-meeting-with-fda-on-stp1/
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005803/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IonQ Expands in EU With Slovakia’s First National Quantum Communication Network8.12.2025 13:05:00 CET | Press release
Partnering with the Slovak Academy of Sciences, IonQ bolsters national security and European quantum communications infrastructure IonQ (NYSE: IONQ), the world’s leading quantum company, through its subsidiary ID Quantique (IDQ), today announced the deployment of Slovakia’s first national quantum communication network. Developed in partnership with the Institute of Physics, Slovak Academy of Sciences (IPSAS), the new system features a resilient hybrid architecture designed to strengthen the country’s cybersecurity infrastructure and support Europe’s quantum digital programs. The Slovak Quantum Communication Infrastructure (skQCI) project represents a major milestone in Slovakia’s contribution to the European Quantum Communication Infrastructure (EuroQCI) initiative, which seeks to establish a secure quantum-resistant communication backbone covering all European Union (EU) member states and territories. By integrating quantum-safe technologies at a national scale, Slovakia will directly
Sagemcom’s SICONIA AMI2.0 Electricity Meter Family Completes Measurement Canada Certification8.12.2025 13:00:00 CET | Press release
Sagemcom, a global leader in smart Electricity, Water and GAS metering solutions, announced that its latest generation of Siconia electricity meters (2S, 12S and 25S) have received type approval from Measurement Canada, confirming compliance with Canadian standards for metering accuracy and reliability. With this certification, Siconia meters can be adopted by utilities across Canada for their AMI deployments. The Siconia meter platform provides extensive modularity in communication technologies and integrated Grid Edge Intelligence. It is engineered in accordance with leading industry standards, enabling seamless interoperability with a broad ecosystem of technology partners. Key Features and Benefits: AMI 2.0 Ready: Enables AI-powered advanced data analytics, remote configuration, and dynamic tariff management. DER Situational Awareness: Detecting and managing resources like solar PV, and EV chargers. Enhanced Operational Efficiency: Real-time monitoring and remote capabilities reduc
KKR Provides €300m Financing for Tristan Capital Partners’ EPISO 6 Acquisition of easyHotel Platform8.12.2025 13:00:00 CET | Press release
KKR, a leading global investment firm, today announced that KKR-managed funds and accounts provided c. €300 million whole loan financing to EPISO 6, a fund managed by Tristan Capital Partners, to support its recent acquisition of easyHotel, a leading pan-European budget hotel operator. The financing will also support growth initiatives for the easyHotel platform, including further advancing the platform’s expansion and investment throughout Europe, new development projects in high-demand markets and capex investment across the existing portfolio. Tristan Capital Partners, a private equity real estate firm, acquired easyHotel, one of Europe’s best-known budget hotel brands, in June 2025 through its latest opportunistic Fund, EPISO 6, in a transaction valued at more than €400 million. The hotel chain focuses on providing affordable, efficient and well-located accommodation for leisure and business travelers. “The easyHotel portfolio combines broad geographic diversification with a proven
IBMI SNQ and ICHOM Forms Strategic Partnership in Asia, Advancing Patient-centered Healthcare in the Region8.12.2025 12:00:00 CET | Press release
The Symbol of National Quality (SNQ), initiated by Taiwan’s Institute for Biotechnology and Medicine Industry (IBMI), has partnered with the International Consortium for Health Outcomes Measurement (ICHOM) to set a new benchmark for healthcare standards across the Asia-Pacific region. The partnership agreement, signed by Chen Wei-Jao, Chief Convener, SNQ Committee, and Jennifer L. Bright, President and CEO of ICHOM, marked a significant collaboration between IBMI SNQ and ICHOM. IBMI SNQ has implemented a rigorous three-stage review system that emphasizes structure, process, and outcomes in recognizing medical teams with world-class achievements. These include liver transplantation, pancreatic cancer surgery, craniofacial reconstruction, atrial fibrillation care, critical care, and gene therapies for rare diseases. Such accomplishments have positioned Taiwan as a global benchmark for healthcare quality, with several treatment protocols adopted into textbooks and incorporated into revisi
Helical Fusion Signs Japan’s First Power Purchase Agreement for Fusion Energy with Aoki Super8.12.2025 10:00:00 CET | Press release
Agreement signals growing market demand for stable, continuous, net-electricity fusion power based on the Helical Stellarator Helical Fusion Co., Ltd. (Headquarters: Tokyo, Japan; “Helical Fusion”), a company developing a commercially viable Helical Stellarator power plant under its “Helix Program”, has signed a Power Purchase Agreement (PPA) with Aoki Super Co., Ltd. (Headquarters: Aichi, Japan; “Aoki Super”), a major regional supermarket chain in central Japan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207372064/en/ Takaya Taguchi (left), CEO of Helical Fusion Co., Ltd. , and Masayuki Kono (right) Managing Director and Head of Administration Division of Aoki Super Co., Ltd. at the press conference held on December 8, 2025 This marks the first fusion-energy PPA ever signed in Japan, representing a concrete step forward in the real-world adoption of fusion energy and signaling growing demand-side engagement in the em
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom